Publications (121) Francisco Gómez Veiga publications

2023

  1. Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial

    European urology oncology, Vol. 6, Núm. 1, pp. 58-66

  2. The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES

    European Urology, Vol. 84, Núm. 2, pp. 229-241

2022

  1. Advances in Urologic Oncology “OncoUrology Forum Special Edition”: The best of 2020

    Actas Urologicas Espanolas, Vol. 46, Núm. 4, pp. 214-222

  2. Effect of LHRH analogs on lower urinary tract symptoms associated with advanced prostate cancer in real clinical practice: ANALUTS study

    Neurourology and Urodynamics, Vol. 41, Núm. 8, pp. 1824-1833

  3. Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk

    Prostate Cancer and Prostatic Diseases, Vol. 25, Núm. 2, pp. 274-282

  4. Improved Survival with Enzalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer

    Journal of Clinical Oncology, Vol. 37

  5. The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups

    Prostate, Vol. 82, Núm. 13, pp. 1237-1247

2021

  1. Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses

    The Journal of urology, Vol. 205, Núm. 5, pp. 1361-1371

  2. La vigilancia activa en pacientes con cáncer de próstata localizado. Análisis de adherencia y salida del protocolo

    Archivos espanoles de urologia, Vol. 74, Núm. 5, pp. 477-487

  3. Mapping the Patient-Oriented Prostate Utility Scale From the Expanded Prostate Cancer Index Composite and the Short-Form Health Surveys

    Value in Health, Vol. 24, Núm. 11, pp. 1676-1685

  4. Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry

    Targeted Oncology, Vol. 16, Núm. 3, pp. 357-367

  5. Reply by Authors

    The Journal of urology, Vol. 205, Núm. 5, pp. 1371

2020

  1. Advances in urologic oncology “OncoForum”: The best of 2019

    Actas Urologicas Espanolas, Vol. 44, Núm. 9, pp. 586-596

  2. Androgen deprivation therapy in patients with localized disease: Comparison with curative intent treatments and time to castration resistance. Results of the Spanish Prostate Cancer Registry

    Actas Urologicas Espanolas, Vol. 44, Núm. 3, pp. 156-163

  3. Efficacité de l’enzalutamide (ENZA) + traitement par suppression androgénique (TSA) dans le cancer de la prostate hormonosensible métastatique (mHSPC) en fonction de la localisation des métastases : analyses post-hoc de l’étude ARCHES

    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, Vol. 30, Núm. 13, pp. 745

  4. Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry

    Targeted Oncology, Vol. 15, Núm. 3, pp. 301-315

  5. The impact of time from biopsy to radical prostatectomy on Gleason score undergrading and other related factors

    Actas Urologicas Espanolas, Vol. 44, Núm. 3, pp. 187-195

2019

  1. Factors related to early castration resistance in metastatic prostate cancer. Results from the National Prostate Cancer Registry in Spain

    Actas Urologicas Espanolas, Vol. 43, Núm. 10, pp. 562-567

  2. Manejo diagnÓstico y actitud terapeÁtica de 1156 pacientes diagnosticados de cÁncer de prÓstata en la comunidad de castilla y leÓn durante el aÑo 2014

    Archivos Espanoles de Urologia, Vol. 72, Núm. 5, pp. 463-470

  3. Prevalence of fatigue and impact on quality of life in castration-resistant prostate cancer patients: The Vital study

    BMC Urology, Vol. 19, Núm. 1